Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 12/01/2023

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

THE HARTFORD HEALTHCARE FUND

HGHCX | Fund

$24.28

$1.13 B

0.00%

$0.00

2.03%

Vitals

YTD Return

-1.8%

1 yr return

-4.4%

3 Yr Avg Return

-1.4%

5 Yr Avg Return

6.8%

Net Assets

$1.13 B

Holdings in Top 10

40.8%

52 WEEK LOW AND HIGH

$24.1
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 2.03%

SALES FEES

Front Load N/A

Deferred Load 1.00%

TRADING FEES

Turnover 51.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

$2,000

IRA

N/A

Fund Classification

Fund Type

Open End Mutual Fund

Name

As of 12/01/2023

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

THE HARTFORD HEALTHCARE FUND

HGHCX | Fund

$24.28

$1.13 B

0.00%

$0.00

2.03%

HGHCX - Profile

Distributions

  • YTD Total Return -1.8%
  • 3 Yr Annualized Total Return -1.4%
  • 5 Yr Annualized Total Return 6.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.12%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    THE HARTFORD HEALTHCARE FUND
  • Fund Family Name
    HARTFORD FUNDS
  • Inception Date
    Aug 09, 2000
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Robert Deresiewicz

Fund Description

Under normal circumstances, the Fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (“Wellington Management”). Wellington Management’s investment process focuses on stock selection through fundamental analysis. The Fund takes a broad approach to investing in the health care sector. The Fund may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors. The Fund’s assets will be allocated across the major subsectors of the health care sector, with some representation typically maintained in each major subsector. The Fund will normally invest at least 25% of its total assets, in the aggregate, in the following industries: pharmaceuticals and biotechnology, medical products and health services. The Fund will invest in securities of issuers located in a number of different countries throughout the world, one of which may be the United States; however, the Fund has no limit on the amount of assets that may be invested in each country. The Fund may invest in securities of companies of any market capitalization.
Read More

HGHCX - Performance

Return Ranking - Trailing

Period HGHCX Return Category Return Low Category Return High Rank in Category (%)
YTD -1.8% -20.2% 14.5% 47.24%
1 Yr -4.4% -26.8% 7.7% 52.76%
3 Yr -1.4%* -31.0% 8.0% 60.26%
5 Yr 6.8%* -10.0% 12.7% 47.41%
10 Yr 8.7%* 0.2% 13.5% 56.07%

* Annualized

Return Ranking - Calendar

Period HGHCX Return Category Return Low Category Return High Rank in Category (%)
2022 -13.7% -53.9% 3.2% 63.46%
2021 -5.9% -39.6% 24.2% 69.23%
2020 3.8% -13.6% 178.2% 86.75%
2019 22.2% 3.8% 63.8% 37.78%
2018 -12.6% -25.3% 21.5% 79.07%

Total Return Ranking - Trailing

Period HGHCX Return Category Return Low Category Return High Rank in Category (%)
YTD -1.8% -20.2% 14.5% 47.24%
1 Yr -4.4% -26.8% 7.7% 52.76%
3 Yr -1.4%* -31.0% 8.0% 60.26%
5 Yr 6.8%* -10.0% 12.7% 47.41%
10 Yr 8.7%* 0.2% 13.5% 56.07%

* Annualized

Total Return Ranking - Calendar

Period HGHCX Return Category Return Low Category Return High Rank in Category (%)
2022 -12.4% -53.9% 3.7% 63.46%
2021 9.1% -33.9% 26.0% 51.92%
2020 21.7% -0.7% 180.6% 54.30%
2019 32.2% 4.6% 63.8% 21.48%
2018 -3.7% -20.6% 22.2% 71.32%

NAV & Total Return History

HGHCX - Holdings

Concentration Analysis

HGHCX Category Low Category High HGHCX % Rank
Net Assets 1.13 B 6.16 M 45 B 43.56%
Number of Holdings 100 24 421 35.58%
Net Assets in Top 10 502 M 1.61 M 20.9 B 46.01%
Weighting of Top 10 40.80% 16.4% 81.7% 73.62%

Top 10 Holdings

  1. UnitedHealth Group Inc 7.40%
  2. Eli Lilly Co 6.71%
  3. Merck Co Inc 5.49%
  4. Danaher Corp 4.29%
  5. Pfizer Inc 4.21%
  6. Zoetis Inc 2.81%
  7. Humana Inc 2.52%
  8. Stryker Corp 2.50%
  9. Thermo Fisher Scientific Inc 2.49%
  10. Boston Scientific Corp 2.39%

Asset Allocation

Weighting Return Low Return High HGHCX % Rank
Stocks 		98.96% 90.39% 106.13% 44.79%
Cash 		0.85% 0.00% 30.53% 71.17%
Other 		0.19% -22.99% 17.97% 25.77%
Preferred Stocks 		0.00% 0.00% 7.86% 81.60%
Convertible Bonds 		0.00% 0.00% 0.37% 75.32%
Bonds 		0.00% 0.00% 12.39% 77.30%

Stock Sector Breakdown

Weighting Return Low Return High HGHCX % Rank
Healthcare 		99.92% 59.26% 100.00% 53.80%
Financial Services 		0.08% 0.00% 1.60% 24.68%
Utilities 		0.00% 0.00% 0.00% 74.68%
Technology 		0.00% 0.00% 22.69% 77.22%
Real Estate 		0.00% 0.00% 5.89% 77.22%
Industrials 		0.00% 0.00% 7.02% 77.22%
Energy 		0.00% 0.00% 0.00% 74.68%
Communication Services 		0.00% 0.00% 9.11% 74.68%
Consumer Defense 		0.00% 0.00% 25.73% 79.11%
Consumer Cyclical 		0.00% 0.00% 1.92% 76.58%
Basic Materials 		0.00% 0.00% 7.16% 84.18%

Stock Geographic Breakdown

Weighting Return Low Return High HGHCX % Rank
US 		90.86% 61.78% 104.41% 61.96%
Non US 		8.09% 0.00% 30.85% 34.36%

HGHCX - Expenses

Operational Fees

HGHCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 2.03% 0.08% 10.48% 17.18%
Management Fee 0.85% 0.03% 1.25% 87.12%
12b-1 Fee 1.00% 0.00% 1.00% 98.72%
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

HGHCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% 100.00%
Deferred Load 1.00% 1.00% 5.00% 95.24%

Trading Fees

HGHCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HGHCX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 51.00% 0.00% 238.00% 58.70%

HGHCX - Distributions

Dividend Yield Analysis

HGHCX Category Low Category High HGHCX % Rank
Dividend Yield 0.00% 0.00% 2.06% 84.05%

Dividend Distribution Analysis

HGHCX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual SemiAnnual Annual

Net Income Ratio Analysis

HGHCX Category Low Category High HGHCX % Rank
Net Income Ratio -1.12% -2.54% 1.85% 90.38%

Capital Gain Distribution Analysis

HGHCX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

HGHCX - Fund Manager Analysis

Managers

Robert Deresiewicz

Start Date

Tenure

Tenure Rank

May 01, 2000

22.1

22.1%

Robert L. Deresiewicz, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 2000. Prior to that, Bob was an Assistant Professor of Medicine at the Harvard Medical School, and an Associate Physician in the Division of Infectious Diseases at the Brigham and Women's Hospital (1990 — 1998). Bob received his MBA from the Harvard Business School (2000), his MD from the Mount Sinai School of Medicine, and his BA in biochemistry summa cum laude from Columbia University.

Ann Gallo

Start Date

Tenure

Tenure Rank

May 01, 2000

22.1

22.1%

Ann C. Gallo, Senior Managing Director, and Global Industry Analyst of Wellington Management, joined as an investment professional in 1998. Prior to that, Ann was a health care analyst with BT Alex. Brown (1995 — 1998). She was an investment banker and a health care analyst at Piper Jaffray in Minneapolis (1992 — 1995). Previously, she was a financial analyst with Citibank N.A. (1991 — 1992) and an accountant with Coopers & Lybrand (1987 — 1989). Ann received her MS from the Massachusetts Institute of Technology and her BS in accounting from Boston College.

Rebecca Sykes

Start Date

Tenure

Tenure Rank

Sep 01, 2020

1.75

1.8%

Rebecca D. Sykes, CFA, Senior Managing Director and Global Industry Analyst of Wellington Management, joined Wellington Management in 2007 and has been an investment professional since 2005.

Wen Shi

Start Date

Tenure

Tenure Rank

Jul 21, 2021

0.86

0.9%

Wen Shi, CFA, Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management for the Fund since 2021 and has been involved in securities analysis for the Fund since 2015. Dr. Shi joined Wellington Management as an investment professional in 2015.

David Khtikian

Start Date

Tenure

Tenure Rank

Mar 01, 2022

0.25

0.3%

David M. Khtikian, CFA, Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management for the Fund since 2022 and has been involved in securities analysis for the Fund since 2013. Mr. Khtikian joined Wellington Management as an investment professional in 2013.

Fayyaz Mujtaba

Start Date

Tenure

Tenure Rank

Mar 01, 2022

0.25

0.3%

Fayyaz Mujtaba, Managing Director and Global Industry Analyst of Wellington Management, has been involved in portfolio management for the Fund since 2022 and has been involved in securities analysis for the Fund since 2013. Mr. Mujtaba joined Wellington Management as an investment professional in 2011.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.84 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.